Hence, these findings demonstrate that breast cancer patients with increased LOXL2 expression have a higher risk to develop recurrence of the disease, and increase in LOXL2 expression is associated with increase in EMT/CSC like markers. This evidence concerns the gene LOXL2 and breast cancer.